Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report-Reference-Cited by-同舟云学术

Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report

Published:2021-11-16 Issue:2 Volume:43 Page:e148-e152
ISSN:1531-7129
Container-title:Otology & Neurotology
language:en
Short-container-title:

Author:

Ding Andy S.,Mahoney Nicholas R.,Campbell Ashley A.,Creighton Francis X.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical),Sensory Systems,Otorhinolaryngology

Reference18 articles.

1. Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy;Rundle;Clin Sci,1945

2. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy;Smith;Best Pract Res Clin Endocrinol Metab,2012

3. Insulin-like growth factor 1: a novel treatment for the protection or regeneration of cochlear hair cells;Yamahara;Hear Res,2015

4. Teprotumumab for the treatment of active thyroid eye disease;Douglas;N Engl J Med,2020

5. Teprotumumab for thyroid-associated ophthalmopathy;Smith;N Engl J Med,2017

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Monoclonal Antibody Usage on Hearing Outcomes: A Systematic Review;The Laryngoscope;2024-09-13

2. A Biologic With Otologic Consequences: Analysis of Hearing Loss and Teprotumumab Using the FDA Adverse Event Reporting System;Otology & Neurotology;2024-09

3. Assessment of Hearing Dysfunction in Patients With Graves’ Disease and Thyroid Eye Disease Without or With Teprotumumab;The Journal of Clinical Endocrinology & Metabolism;2024-08-14

4. Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment;The Journal of Clinical Endocrinology & Metabolism;2024-06-15

5. An observational study on the safety of teprotumumab based on FAERS database;Endocrine;2024-05-17